The HTATIP2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung adenocarcinoma A-549 cell line. This genetically engineered model features targeted disruption of the HTATIP2 gene, which encodes a tumor suppressor protein with oxidoreductase activity involved in apoptosis, proliferation, and metabolic regulation. The polyclonal format provides a heterogeneous pool of edited cells, enabling robust loss-of-function studies without clonal artifacts.
The parental A-549 cell line is a widely used model in respiratory research, established from the lung adenocarcinoma of a 58-year-old Caucasian male. These cells exhibit alveolar type II-like epithelial characteristics and retain key features of lung adenocarcinoma, including oncogenic signaling activation and altered metabolic profiles. Their well-characterized biology and responsiveness to various stimuli make them an ideal platform for investigating tumor suppressive pathways.
HTATIP2 functions as a critical tumor suppressor, primarily by negatively regulating the PI3K/AKT signaling axis. It is transcriptionally activated by upstream regulators TP53 and EGR1, and in turn suppresses downstream effectors AKT1, cyclin D1 (CCND1), and the anti-apoptotic protein BCL2, while promoting the activity of pro-apoptotic BAX and CASP3. HTATIP2 also attenuates cell migration and invasion by repressing CDC42 activity and expression of MMP2 and MMP9. Interacting partners such as EEF1A1, NOP53, PSMC5, and CTNNB1 connect it to translational control, p53 signaling, and Wnt/??-catenin pathways, positioning HTATIP2 as a central coordinator of cell survival, proliferation, and motility.
In the A-549 background, loss of HTATIP2 is expected to release inhibition of AKT/mTOR signaling, leading to enhanced proliferation, survival, and metabolic adaptation. This knockout model recapitulates tumor suppressor inactivation observed in lung adenocarcinoma and other cancers, providing a relevant system to dissect the molecular consequences of HTATIP2 loss. The oncogenic background of A-549 cells may cooperate with HTATIP2 disruption to exacerbate malignant phenotypes, enabling studies of synergistic effects and identification of therapeutic vulnerabilities.
Researchers can employ this polyclonal knockout population to investigate tumor suppressor mechanisms, apoptosis regulation, and metabolic reprogramming in lung adenocarcinoma. Representative assays include western blotting for HTATIP2, AKT, and downstream targets; RT-qPCR for gene expression analysis; Annexin V/propidium iodide apoptosis assays; MTT proliferation assays; Transwell migration/invasion assays; phospho-AKT flow cytometry; cell cycle profiling; and metabolic flux analysis. These tools enable evaluation of drug sensitivity, epithelial-mesenchymal transition, and crosstalk with extracellular signals. For further information or technical support, please contact Ascent Research.
